ADBioHub
Login / Register
@ProfileFirstName @ProfileLastName

X

  • Edit profile
  • Consent
  • Security
  • Logout
  • Understand the Alzheimer’s continuum and MCI
  • Detect Alzheimer’s disease early
  • Unravel the neuropathology of Alzheimer’s disease
  • Explore biomarker testing for Alzheimer’s disease
  • See the future of Alzheimer’s disease
  • Discover what’s new
    • Discover registered
    • Discover Public

The new conversation in Alzheimer’s disease

01

Understand

Understand

Alzheimer’s disease is now considered to form a continuum, encompassing pathological preclinical changes, mild cognitive impairment (MCI) and AD dementia. How might this change AD diagnosis and management?

02

Detect

Detect

New diagnostic technologies have to potential to detect Alzheimer’s disease at an earlier stage. Explore the latest research and what this may mean for patient management.

03

Unravel

Unravel

The neuropathology of Alzheimer’s disease remains an unresolved topic. Unravel the latest findings and controversies with the experts and gain insight into future research directions.

04

Explore

Explore

Explore biomarker testing

Future

05

Future

Future

As we learn more about Alzheimer’s disease, the way we diagnose and manage the condition is likely to change. Discover innovative ways Australians are preparing for the challenges that lie ahead.

Discover

06

Discover

Discover

ADBioHub brings you exclusive news, views and insights from Australia’s leading Alzheimer’s experts. Stay up to date with our latest content, including webinars, podcasts, articles and videos.

For Australian-registered Healthcare Professionals.

Questions? Contact our Medical Team at
adbiohub@biogen.com

GET IN TOUCH

Contact

Privacy policy

Terms and Conditions

Contact

Privacy policy

Terms and Conditions

Сookies

Biogen Australia Pty Ltd. ABN 30 095 760 115. Macquarie Park, NSW.
Biogen® is a registered trademark of Biogen MA Inc. © Biogen-100435. Date of preparation: April 2021.